Novartis’ slow-rolling Kymriah wins coverage in Japan at $305K: report
After snagging the first Japanese CAR-T approval in March, Novartis has won the go-ahead to sell its groundbreaking med, Kymriah, under the country’s national insurance system. And that gives the brand a chance to boost lagging sales. The Central Social Insurance Medical Council of Japan’s Ministry of Health, Labor and Welfare has approved coverage of… Read More »